AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33920994 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical pesticide use; 84% of farmers used exclusively chemical pesticides.
Number of subjects: 790
Study 33920994 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsafe practices of pesticide handling; farmers with unsafe practices were two times more likely to suffer from acute poisoning.
Number of subjects: 790
Study 33920994 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception/attitude towards chemical pesticide policy and market management; significantly associated with safe practices.
Number of subjects: 790
Study 32970396 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg once daily)
Number of subjects: 4304
Study 32970396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4304
Study 32970396 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4304
Study 35710247 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse or allied health professional-led follow-up appointment 4 weeks after TIA/minor stroke, including a needs checklist, action plan, resources, GP letter, and training.
Number of subjects: 60
Study 35710247 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study 35672161 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal (SCB)
Number of subjects: 15
Study 35672161 — intervention group
Group type: COMPARATOR
Intervention: Clearfil SE Bond (B; negative control)
Number of subjects: 15
Study 35672161 — intervention group
Group type: EXPERIMENTAL
Intervention: ESPE Sil (S)
Number of subjects: 15
Study 35672161 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Ceramic Primer Plus (CPP)
Number of subjects: 15
Study 35672161 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Repair (CR)
Number of subjects: 15
Study 35672161 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond bur (D)
Number of subjects: 15
Study 35672161 — intervention group
Group type: EXPERIMENTAL
Intervention: Airborne abrasion (A)
Number of subjects: 15
Study 35672161 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribochemical silica coating (T)
Number of subjects: 15
Study 34284783 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory patient care plan
Number of subjects: 605
Study 34284783 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 605
Study 32406728 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Physical Activity (PPA) intervention
Number of subjects: 1983
Study 34738192 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaspoon labelling
Number of subjects: 563
Study 34738192 — intervention group
Group type: COMPARATOR
Intervention: Plain labelling
Number of subjects: 563
Study 34738192 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% increase in SSB prices
Number of subjects: 563
Study 33580923 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical latanoprost 0.005% ophthalmic solution
Number of subjects: 50
Study 33580923 — intervention group
Group type: COMPARATOR
Intervention: Topical betamethasone diproprionate 0.05% lotion
Number of subjects: 50
Study 34672899 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling + Recreational Physical Activity Group (CPAG)
Number of subjects: 74
Study 34672899 — intervention group
Group type: COMPARATOR
Intervention: Counseling Group (CG)
Number of subjects: 74
Study 34672899 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (CG and CPAG)
Number of subjects: 74
Study 33386947 — intervention group
Group type: EXPERIMENTAL
Intervention: mirabegron
Number of subjects: 91
Study 33386947 — intervention group
Group type: COMPARATOR
Intervention: anticholinergics
Number of subjects: 91
Study 35262625 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel dose de-escalation (5 mg daily) at 1 month post-PCI
Number of subjects: 2271
Study 35262625 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (10 mg daily)
Number of subjects: 2271
Study 33729570 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine needle aspiration cytology (FNAC)
Number of subjects: 104
Study 33729570 — intervention group
Group type: COMPARATOR
Intervention: Fine needle non-aspiration cytology (FNNAC)
Number of subjects: 104
Study 32019599 — intervention group
Group type: EXPERIMENTAL
Intervention: HO‐1‐transfected UCMSCs
Number of subjects: 0
Study 32019599 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisomycin
Number of subjects: 0
Study 32019599 — intervention group
Group type: COMPARATOR
Intervention: shHO‐1 transfected UCMSCs
Number of subjects: 0
Study 32019599 — intervention group
Group type: COMPARATOR
Intervention: SP600125
Number of subjects: 0
Study 33987879 — intervention group
Group type: EXPERIMENTAL
Intervention: Training cohort with bladder neck position on Valsalva, Vectors 3, and BMI
Number of subjects: 300
Study 33987879 — intervention group
Group type: EXPERIMENTAL
Intervention: Funneling and Vector 3
Number of subjects: 300
Study 33987879 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model incorporating funneling, Vectors 3, and BMI
Number of subjects: 300
Study 33987879 — intervention group
Group type: EXPERIMENTAL
Intervention: Hiatal area (HA)
Number of subjects: 300
Study 33987879 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-urethral mobility
Number of subjects: 300
Study 34165199 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg
Number of subjects: 32
Study 34165199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 34997899 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-Delivered Acceptance and Commitment Therapy (iACT)
Number of subjects: 0
Study 34997899 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (iFORUM)
Number of subjects: 0
Study 33618197 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-onset regular tobacco smokers
Number of subjects: 0
Study 33618197 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset regular tobacco smokers
Number of subjects: 0
Study 33618197 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset regular cannabis users
Number of subjects: 0
Study 32202510 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-mono (ritonavir-boosted protease inhibitors)
Number of subjects: 85
Study 32202510 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy
Number of subjects: 85
Study 35441486 — intervention group
Group type: EXPERIMENTAL
Intervention: Theranova 400 dialyzer
Number of subjects: 171
Study 35441486 — intervention group
Group type: COMPARATOR
Intervention: High-flux dialyzer
Number of subjects: 171
Study 35010881 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt Control H equipment used to monitor and control salt during cooking for 8 weeks
Number of subjects: 114
Study 35010881 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 114
Study 35318869 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSIP (Attempted Suicide Short Intervention Program)
Number of subjects: 239
Study 35318869 — intervention group
Group type: COMPARATOR
Intervention: Crisis Counselling (CC)
Number of subjects: 239
Study 34405305 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid antagonist naltrexone (50 mg)
Number of subjects: 84
Study 34405305 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 84
Study 34237249 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT plus pembrolizumab and trametinib
Number of subjects: 170
Study 34237249 — intervention group
Group type: COMPARATOR
Intervention: SBRT plus gemcitabine
Number of subjects: 170
Study 32274491 — intervention group
Group type: EXPERIMENTAL
Intervention: Single low level laser therapy
Number of subjects: 60
Study 32274491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 35639947 — intervention group
Group type: EXPERIMENTAL
Intervention: No dressing (intervention group)
Number of subjects: 754
Study 35639947 — intervention group
Group type: COMPARATOR
Intervention: Tamponade dressing (control group)
Number of subjects: 754
Study 34109364 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 μg/kg)
Number of subjects: 50
Study 34109364 — intervention group
Group type: COMPARATOR
Intervention: Midazolam + Fentanyl (0.02 mg/kg midazolam and 2.0 μg/kg fentanyl)
Number of subjects: 50
Study 33308259 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE)
Number of subjects: 16
Study 33308259 — intervention group
Group type: COMPARATOR
Intervention: Control group (ND)
Number of subjects: 16
Study 33406539 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping
Number of subjects: 180
Study 33406539 — intervention group
Group type: COMPARATOR
Intervention: Umbilical cord milking
Number of subjects: 180
Study 33406539 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age (GA)
Number of subjects: 180
Study 33406539 — intervention group
Group type: EXPERIMENTAL
Intervention: Small for gestational age (SGA) infants
Number of subjects: 180
Study 33406539 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight
Number of subjects: 180
Study 35655280 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 287
Study 35655280 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical treatment
Number of subjects: 287
Study 32591406 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat head position (FP)
Number of subjects: 867
Study 36031952 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led educational intervention
Number of subjects: 128
Study 36031952 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study 34242246 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) monotherapy
Number of subjects: 39
Study 34242246 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor inhibitors (TNFi) in combination with MTX
Number of subjects: 39
Study 32358482 — intervention group
Group type: EXPERIMENTAL
Intervention: LGI 2 biscuits (GI 24)
Number of subjects: 13
Study 32358482 — intervention group
Group type: COMPARATOR
Intervention: LGI 1 biscuits (GI 54)
Number of subjects: 13
Study 35856483 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermapen and topical coconut oil
Number of subjects: 24
Study 35856483 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermapen and topical sesame oil
Number of subjects: 24
Study 35856483 — intervention group
Group type: COMPARATOR
Intervention: Periodontal mechanical treatment only
Number of subjects: 24
Study 35856483 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 24
Study 33058259 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor wood smoke reduction intervention
Number of subjects: 0
Study 33058259 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 0
Study 33993790 — intervention group
Group type: EXPERIMENTAL
Intervention: modified dynamic needle tip positioning short-axis
Number of subjects: 90
Study 33993790 — intervention group
Group type: COMPARATOR
Intervention: long-axis
Number of subjects: 90
Study 32122703 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation treatment (GaAs diode laser, continuous wave 980nm, power 100mW, energy density 12J/cm2, applied on days 1, 3, 7, 14, 21, and 28 postoperatively)
Number of subjects: 18
Study 32122703 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation treatment
Number of subjects: 18
Study 32122703 — intervention group
Group type: COMPARATOR
Intervention: Control side (laser probe turned off)
Number of subjects: 18
Study 36327046 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuqinxi exercise (60 min/session, once a week for 40 weeks)
Number of subjects: 50
Study 36327046 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control group
Number of subjects: 50
Study 33793678 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antiviral and nonsteroidal anti-inflammatory treatment
Number of subjects: 0
Study 33793678 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32811529 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural mothers
Number of subjects: 630
Study 32811529 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with no formal education
Number of subjects: 630
Study 32811529 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall U5 children with fever
Number of subjects: 630
Study 32811529 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with poor malaria knowledge
Number of subjects: 630
Study 32811529 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with poor perception of malaria
Number of subjects: 630
Study 32811529 — intervention group
Group type: EXPERIMENTAL
Intervention: Household size > 5
Number of subjects: 630
Study 34816478 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment and Hall Technique (ART/HT)
Number of subjects: 338
Study 34816478 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 338
Study 35264075 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic-rich yogurt (100g daily for 6 weeks)
Number of subjects: 60
Study 35264075 — intervention group
Group type: COMPARATOR
Intervention: Regular yogurt (control)
Number of subjects: 60
Study 32208178 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Engagement Studio (CE Studio)
Number of subjects: 13
Study 32208178 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational videos created in response to parental comments
Number of subjects: 13
Study 36450626 — intervention group
Group type: COMPARATOR
Intervention: cobimetinib (cobi) 60 mg/day on days 1-21
Number of subjects: 49
Study 36450626 — intervention group
Group type: EXPERIMENTAL
Intervention: cobimetinib (cobi) 40 mg/day on days 1-21 + venetoclax (ven) 800 mg/day on days 1-28
Number of subjects: 49
Study 36450626 — intervention group
Group type: EXPERIMENTAL
Intervention: cobimetinib (cobi) 40 mg/day on days 1-21 + venetoclax (ven) 800 mg/day on days 1-28 + atezolizumab (atezo) 840 mg on days 1 and 15 of 28-day cycles
Number of subjects: 49
Study 34772434 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver educational intervention based on the Integrative Model of Behavioral Prediction (IMBP)
Number of subjects: 46
Study 34772434 — intervention group
Group type: COMPARATOR
Intervention: Supplementary low-protein-modified foods
Number of subjects: 46
Study 34772434 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver educational intervention
Number of subjects: 46
Study 32679370 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine treatment
Number of subjects: 194
Study 32679370 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 194
Study 35625055 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic sitting exercise with 500-ms-delayed visual feedback (30 times/day, 5 days/week)
Number of subjects: 27
Study 35625055 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic sitting exercise with 500-ms-delayed visual feedback
Number of subjects: 27
Study 35625055 — intervention group
Group type: COMPARATOR
Intervention: Real-time visual feedback (control group)
Number of subjects: 27
Study 32536150 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir
Number of subjects: 65
Study 32536150 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine
Number of subjects: 65
Study 35902299 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene with acupuncture
Number of subjects: 1000
Study 34375706 — intervention group
Group type: EXPERIMENTAL
Intervention: Major infection group (patients who experienced major infections)
Number of subjects: 1517
Study 34375706 — intervention group
Group type: COMPARATOR
Intervention: No major infection group (patients who did not experience major infections)
Number of subjects: 1517
Study 34375706 — intervention group
Group type: EXPERIMENTAL
Intervention: Major infection group (with periprocedural major infections)
Number of subjects: 1517
Study 34375706 — intervention group
Group type: COMPARATOR
Intervention: No major infection group (without periprocedural major infections)
Number of subjects: 1517
Study 35766041 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure (SBP) goal <120 mm Hg
Number of subjects: 9361
Study 35766041 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic blood pressure (SBP) goal <140 mm Hg
Number of subjects: 9361
Study 34584881 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil combined with Xingpi Yanger granules
Number of subjects: 124
Study 32586153 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy with coronary angiography and optimal medical treatment
Number of subjects: 186
Study 32586153 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy with only optimal medical treatment
Number of subjects: 186
Study 32586153 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 186
Study 32052831 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 250 mg intramuscular single dose and doxycycline for 14 days plus metronidazole for 14 days
Number of subjects: 233
Study 32052831 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 250 mg intramuscular single dose and doxycycline for 14 days
Number of subjects: 233
Study 34489276 — intervention group
Group type: EXPERIMENTAL
Intervention: del Nido
Number of subjects: 90
Study 34489276 — intervention group
Group type: EXPERIMENTAL
Intervention: modified del Nido
Number of subjects: 90
Study 34489276 — intervention group
Group type: EXPERIMENTAL
Intervention: Custodiol
Number of subjects: 90
Study 35713267 — intervention group
Group type: EXPERIMENTAL
Intervention: IIP + CTG
Number of subjects: 30
Study 35713267 — intervention group
Group type: COMPARATOR
Intervention: IIP
Number of subjects: 30
Study 34258686 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous antibiotic infusion (CAI) via an ambulatory pump
Number of subjects: 40
Study 34258686 — intervention group
Group type: COMPARATOR
Intervention: Standard pump and intermittent antibiotic administration (IAA)
Number of subjects: 40
Study 32514012 — intervention group
Group type: EXPERIMENTAL
Intervention: AT2R
Number of subjects: 0
Study 32514012 — intervention group
Group type: EXPERIMENTAL
Intervention: Klf‐5/IRF‐1 and circErbB4/miR-29a-5p
Number of subjects: 0
Study 34962679 — intervention group
Group type: EXPERIMENTAL
Intervention: Unused healing abutment
Number of subjects: 72
Study 34962679 — intervention group
Group type: COMPARATOR
Intervention: Reused healing abutment
Number of subjects: 72
Study 33253659 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive intraoperative peritoneal lavage (EIPL) with 1 L of warm normal 0.9% saline, repeated ten times after surgery.
Number of subjects: 800
Study 33253659 — intervention group
Group type: COMPARATOR
Intervention: Standard surgery (surgery alone).
Number of subjects: 800
Study 33253659 — intervention group
Group type: EXPERIMENTAL
Intervention: EIPL group (adverse events).
Number of subjects: 800
Study 33253659 — intervention group
Group type: COMPARATOR
Intervention: Standard surgery group (adverse events).
Number of subjects: 800
Study 33583347 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporarily Hostile (TH) group, primed with negative words
Number of subjects: 38
Study 33583347 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporarily Non-Hostile (TNH) group, primed with positive words
Number of subjects: 38
Study 32252697 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (81±5.5 years)
Number of subjects: 78
Study 32252697 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (44±3.2 years)
Number of subjects: 78
Study 32252697 — intervention group
Group type: COMPARATOR
Intervention: Group C (21±2.5 years)
Number of subjects: 78
Study 36058253 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical LV unloading with the Impella CP device for 30 minutes prior to primary PCI
Number of subjects: 668
Study 36058253 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI alone without LV unloading
Number of subjects: 668
Study 36058253 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella CP-related major bleeding or major vascular complications within 30 days
Number of subjects: 668
Study 34327527 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous mechanical circulatory support (pMCS) by Impella CP
Number of subjects: 48
Study 34327527 — intervention group
Group type: COMPARATOR
Intervention: Intra-aortic balloon pump (IABP)
Number of subjects: 48
Study 34327527 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous mechanical circulatory support (pMCS)
Number of subjects: 48
Study 34327527 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (pMCS and IABP)
Number of subjects: 48
Study 32303763 — intervention group
Group type: EXPERIMENTAL
Intervention: ALM 100 mg
Number of subjects: 202
Study 32303763 — intervention group
Group type: EXPERIMENTAL
Intervention: ALM 200 mg
Number of subjects: 202
Study 32303763 — intervention group
Group type: EXPERIMENTAL
Intervention: ZOL 10 mg
Number of subjects: 202
Study 32303763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 34841598 — intervention group
Group type: EXPERIMENTAL
Intervention: SUB group (n=18) - substituted pecans for isocaloric foods from their habitual diet
Number of subjects: 56
Study 34841598 — intervention group
Group type: EXPERIMENTAL
Intervention: ADD group (n=16) - consumed pecans as part of a free‐living diet
Number of subjects: 56
Study 34841598 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=18) - nut-free
Number of subjects: 56
Study 34950734 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial intervention
Number of subjects: 59
Study 34950734 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 59
Study 34950734 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study 33915514 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe to profound preoperative hearing loss (PTA > 70 dB HL)
Number of subjects: 57
Study 33915514 — intervention group
Group type: COMPARATOR
Intervention: Control group with preoperative serviceable hearing
Number of subjects: 57
Study 33915514 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative profound hearing loss
Number of subjects: 57
Study 32232781 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal low‐frequency, high‐intensity direct observation and coaching intervention
Number of subjects: 100